21世纪经济报道记者 季媛媛随着中国创新药企在肿瘤与自身免疫疗法领域的激烈竞争,这些企业正从依赖故事营销转向以数据驱动的创新战略,同时采取多元化的融资策略以确保生存和发展。“资本寒冬教训深刻,企业更注重管线聚焦、数据差异化及现金流管理,从‘讲故事’转向‘拼数据’。”有业内人士点出了当前Biotech企业的生存法则。Wind数据显示,截至9月15日,年内在港上市的61家公司中,按第18A章规则上市的...
Source Link21世纪经济报道记者 季媛媛随着中国创新药企在肿瘤与自身免疫疗法领域的激烈竞争,这些企业正从依赖故事营销转向以数据驱动的创新战略,同时采取多元化的融资策略以确保生存和发展。“资本寒冬教训深刻,企业更注重管线聚焦、数据差异化及现金流管理,从‘讲故事’转向‘拼数据’。”有业内人士点出了当前Biotech企业的生存法则。Wind数据显示,截至9月15日,年内在港上市的61家公司中,按第18A章规则上市的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.